You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 23, 2024

CLINICAL TRIALS PROFILE FOR ZINC CHLORIDE IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Zinc Chloride In Plastic Container

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed Cystic Fibrosis Foundation Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed Cystic Fibrosis Foundation Therapeutics Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
New Combination NCT00016744 ↗ Phenylbutyrate/Genistein Duotherapy in Delta F508-Homozygous(for Cystic Fibrosis) Completed National Center for Research Resources (NCRR) Phase 1/Phase 2 2001-09-01 We are testing a new combination of medicines, to determine if they could be used to treat cystic fibrosis (CF). Subjects with CF who have two copies of the most common mutation (change) found in patients with CF called DF508. CF is caused by a lack of chloride movement in the nose, sinuses, lungs, intestines, pancreas and sweat glands. We are conducting this study to determine the safety of using a combination of two medicines, Phenylbutyrate and Genistein, to improve the ability of the cells lining the nose to regulate movement of salt (chloride) and water in people with CF. Phenylbutyrate has been extensively used to treat patients with rare metabolic diseases (which are very different from CF), Phenylbutyrate is an investigational drug for the purpose of this study. Genistein is a naturally occurring substance that is found in food products such as soy and tofu, but is also an investigational drug for this study. Both drugs may be able to restore normal chloride movements in body organs and glands. We will be studying salt and water in the nose movement by a technique called nasal transepithelial potential difference (NPD).
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Zinc Chloride In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Zinc Chloride In Plastic Container

Condition Name

Condition Name for Zinc Chloride In Plastic Container
Intervention Trials
Cystic Fibrosis 49
Healthy 27
Pain 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Zinc Chloride In Plastic Container
Intervention Trials
Fibrosis 51
Cystic Fibrosis 50
Kidney Diseases 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Zinc Chloride In Plastic Container

Trials by Country

Trials by Country for Zinc Chloride In Plastic Container
Location Trials
United States 810
China 57
Germany 49
Australia 49
Canada 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Zinc Chloride In Plastic Container
Location Trials
California 64
Texas 57
Illinois 36
Florida 35
North Carolina 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Zinc Chloride In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Zinc Chloride In Plastic Container
Clinical Trial Phase Trials
Phase 4 192
Phase 3 133
Phase 2/Phase 3 26
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Zinc Chloride In Plastic Container
Clinical Trial Phase Trials
Completed 418
Recruiting 122
Unknown status 67
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Zinc Chloride In Plastic Container

Sponsor Name

Sponsor Name for Zinc Chloride In Plastic Container
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 13
Vertex Pharmaceuticals Incorporated 12
Allergan 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Zinc Chloride In Plastic Container
Sponsor Trials
Other 963
Industry 298
NIH 46
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.